ONCO Stock Overview A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Onconetix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Onconetix Historical stock prices Current Share Price US$0.34 52 Week High US$21.40 52 Week Low US$0.33 Beta 3.25 1 Month Change -46.03% 3 Month Change -94.30% 1 Year Change -95.82% 3 Year Change n/a 5 Year Change n/a Change since IPO -99.99%
Recent News & Updates
Onconetix Provides Non-Compliance Update with Listing Rule 5250(c)(1) Dec 13 Onconetix, Inc. announced delayed 10-Q filing Nov 16
High number of new and inexperienced directors Nov 14
Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(a)(1) Oct 10 Onconetix, Inc. announced that it expects to receive $27 million in funding Oct 04
Onconetix Provides Non-Compliance Update Sep 25 See more updates
Onconetix Provides Non-Compliance Update with Listing Rule 5250(c)(1) Dec 13 Onconetix, Inc. announced delayed 10-Q filing Nov 16
High number of new and inexperienced directors Nov 14
Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(a)(1) Oct 10 Onconetix, Inc. announced that it expects to receive $27 million in funding Oct 04
Onconetix Provides Non-Compliance Update Sep 25 Onconetix, Inc. announced that it expects to receive $5 million in funding Sep 05
Onconetix, Inc. announced delayed 10-Q filing Aug 15
Onconetix, Inc., Annual General Meeting, Sep 05, 2024 Aug 02 Onconetix, Inc. announced delayed 10-Q filing May 17
Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1) May 14 Onconetix, Inc. announced delayed annual 10-K filing Apr 02
High number of new and inexperienced directors Mar 01
High number of new and inexperienced directors Feb 15 Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors Onconetix, Inc. Announces Chief Executive Officer Changes
Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer Dec 29
Onconetix, Inc. Announces Executive Appointments Dec 23
Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index Dec 22 Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG. Dec 19
Blue Water Biotech, Inc. announced delayed 10-Q filing Nov 17
High number of new and inexperienced directors Nov 15 Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO
Blue Water Biotech Receives Non-Compliance Notice from Nasdaq Sep 23
Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q Aug 29 Blue Water Biotech, Inc. Announces Executive Changes
Blue Water Biotech, Inc. announced delayed 10-Q filing Aug 17
New major risk - Shareholder dilution Aug 06
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products Jul 08
Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate Jun 29
New major risk - Share price stability Jun 16
Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC. Jun 15
New major risk - Financial position Jun 08
Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development Feb 07
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation Jan 24
Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors Jan 18
High number of new and inexperienced directors Nov 16
Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares. Nov 11
Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors Nov 09
Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona Oct 12
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia Oct 11
CEO, President & Executive Chairman recently sold US$2.6m worth of stock Aug 24
Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors Aug 23
CEO, President & Executive Chairman notifies of intention to sell stock Aug 22
Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate Aug 18
Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot Aug 17 Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding Aug 12
Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding Aug 10
Blue Water Vaccines in pact to study Alzheimer’s vaccine Jul 20
Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022 Jul 19
Blue Water Vaccines: Estimates And Expectations May 17
High number of new and inexperienced directors Apr 27
Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC Apr 22 Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding Apr 20
Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding Apr 15
High number of new and inexperienced directors Apr 01
High number of new and inexperienced directors Mar 03
Blue Water Vaccines, Inc. Announces Board Changes Feb 26
Less than half of directors are independent Feb 23 Blue Water Vaccines, Inc. has completed an IPO in the amount of $19.999998 million. Feb 19
Shareholder Returns ONCO US Biotechs US Market 7D -5.6% 2.1% 2.8% 1Y -95.8% -3.8% 24.5%
See full shareholder returns
Return vs Industry: ONCO underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: ONCO underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is ONCO's price volatile compared to industry and market? ONCO volatility ONCO Average Weekly Movement 30.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ONCO's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Show more Onconetix, Inc. Fundamentals Summary How do Onconetix's earnings and revenue compare to its market cap? ONCO fundamental statistics Market cap US$2.82m Earnings (TTM ) -US$51.60m Revenue (TTM ) US$1.87m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ONCO income statement (TTM ) Revenue US$1.87m Cost of Revenue US$2.60m Gross Profit -US$732.03k Other Expenses US$50.87m Earnings -US$51.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.22 Gross Margin -39.13% Net Profit Margin -2,758.66% Debt/Equity Ratio 24.3%
How did ONCO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 22:05 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Vernon Bernardino H.C. Wainwright & Co. Jason McCarthy Maxim Group
Show 0 more analysts 
